Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: A retrospective study and in vitro activities of antimicrobial combinations

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Cho, Sung Yeon ^a   Lee, Dong Gun ^a   Choi, Su Mi ^a   Park, Chulmin ^a   Chun, Hye Sun ^a   Park, Yeon Joon ^a   Choi, Jae Ki ^a   Lee, Hyo Jin ^a   Park, Sun Hee ^a   Choi, Jung Hyun ^a   Yoo, Jin Hong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Bacteremia; Drug combinations; Hematologic diseases; Mortality; Stenotrophomonas maltophilia

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TIMENTIN; ANTIINFECTIVE AGENT; DRUG COMBINATION;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ASSAY; BLOODSTREAM INFECTION; BROTH DILUTION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FRACTIONAL INHIBITORY CONCENTRATION; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT BIOLUMINESCENCE ASSAY; HUMAN; IN VITRO STUDY; INCIDENCE; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEUTROPENIA; PNEUMONIA; RETROSPECTIVE STUDY; SHOCK; STENOTROPHOMONAS MALTOPHILIA; ADOLESCENT; BACTEREMIA; COMPLICATION; DRUG COMBINATION; EVALUATION STUDY; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMATOLOGIC DISEASE; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG COMBINATIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928658419     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0801-7     Document Type: Article

References (32)

1. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45:1602-9.
2. Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9:312-23.
3. Kwon JC, Kim SH, Choi JK, Cho SY, Park YJ, Park SH, et al. Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center. Infect Chemother. 2013;45:51-61.
4. Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin Microbiol Infect Dis. 2010;29:605-8.
5. Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34:1653-6.
6. Garazi M, Singer C, Tai J, Ginocchio CC. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012;81:114-8.
7. Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;98:1836-47.
8. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother. 2008;62:889-94.
9. Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant gram-negatice pathogens. Infect Chemother. 2014;46:149-64.
10. Cho SY, Kang CI, Kim J, Ha YE, Chung DR, Lee NY, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58:581-3.
11. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-93.
12. Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011;26:220-52.
13. Ito JI, Tegtmeier BR, O'Donnell MR. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med. 2006;354:90-4.
14. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25:2-41.
15. Church D, Lloyd T, Peirano G, Pitout J. Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis. 2013;45:265-70.
16. Whitby PW, Carter KB, Burns JL, Royall JA, LiPuma JJ, Stull TL. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol. 2000;38:4305-9.
17. Adamek M, Overhage J, Bathe S, Winter J, Fischer R, Schwartz T. Genotyping of environmental and clinical Stenotrophomonas maltophilia isolates and their pathogenic potential. PLoS One. 2011;6:e27615.
18. Kumar S, Tamura K, Nei M. Mega3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform. 2004;5:150-63.
19. Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol. 1998;36:1953-8.
20. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233-9.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI document M100-S23. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2013.
22. Poulos CD, Matsumura SO, Willey BM, Low DE, McGeer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother. 1995;39:2220-3.
23. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis. 2001;41:71-8.
24. Moody JA. Synergism testing: Broth microdilution checkerboard and broth macrodilution methods. In: Garcia LS, Isenberg HD, editors. Clinical microbiology procedures handbook. Washington, DC: ASM Press; 2007. p. 1-23.
25. Lai CH, Wong WW, Chin C, Huang CK, Lin HH, Chen WF, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect. 2006;12:986-91.
26. Kim SH, Yoon YK, Kim MJ, Shon JW. Risk factors for and clinical implications of mixed candida/bacterial bloodstream infections. Clin Microbiol Infect. 2013;19:62-8.
27. Ortega M, Rovira M, Almela M, Marco F, de la Bellacasa JP, Martínez JA, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol. 2005;84:40-6.
28. Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45:47-53.
29. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010;54:2735-7.
30. Di Bonaventura G, Spedicato I, D'Antonio D, Robuffo I, Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother. 2004;48:151-60.
31. Wu K, Yau YC, Matukas L, Waters V. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2013;57:1546-8.
32. Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol. 2007;5:127-36.